Prostate Cancer Treatment Options: How to Avoid Regret and Preserve Quality of Life

Most men diagnosed with prostate cancer are quickly led into a very familiar conversation. The path usually looks the same. Biopsy. Surgery. Radiation. Hormone suppression. The underlying assumption is rarely challenged. Find the cancer, attack the cancer, and eliminate it as quickly as possible.

At first glance, that approach sounds logical. It feels decisive and reassuring because it gives men the impression that aggressive action automatically leads to better outcomes. But this is where I believe prostate cancer care often gets the conversation wrong. The issue is not whether prostate cancer can be treated. The issue is whether aggressive intervention consistently delivers meaningful long-term benefit relative to the cost.

After years of treating men and studying prostate cancer, I have become increasingly convinced of something that many in conventional medicine are uncomfortable discussing openly: guaranteed harm with uncertain benefit is not good medicine.

If a treatment predictably carries significant risk to urinary function, sexual health, strength, energy, and overall quality of life, then the expected benefit should be clear. Men deserve to understand not only what a treatment aims to accomplish, but also what it may cost them physically and functionally over the long term.

This is why the most important question is not simply whether prostate cancer should be treated. The more important question is whether a treatment strategy meaningfully improves long-term outcomes while preserving the things that matter most, including strength, vitality, independence, and quality of life. That is a very different conversation, and it is the one more men should be having.

Why Conventional Prostate Cancer Treatment Often Disappoints

For many men with early-stage prostate cancer, aggressive treatment does not meaningfully improve long-term survival, yet it frequently comes with life-changing consequences. The landmark ProtecT trial, published in The New England Journal of Medicine, found no significant difference in prostate cancer mortality between active monitoring, surgery, and radiation therapy after 15 years of follow-up for localized disease.

Men underwent dramatically different treatment strategies, yet long-term survival outcomes remained remarkably similar in many cases. What changed far more significantly was not survival, but quality of life.

If long-term survival is often similar, then what exactly are we gaining, and what are we potentially sacrificing?

Research from the 10-year CEASAR follow-up, published in JAMA, reinforced what many men experience but are not always fully told before treatment: the effects of prostate cancer treatment can persist for years. Men who underwent radical prostatectomy had significantly worse long-term urinary incontinence, while sexual dysfunction remained common across multiple treatment groups, including surgery and radiation. Although some side effects improved over time, meaningful differences in urinary, sexual, and bowel function continued years after treatment. These are not minor side effects or temporary inconveniences. They directly affect quality of life, daily function, relationships, confidence, and long-term well-being.

Urinary dysfunction, erectile dysfunction, fatigue, loss of strength, hormonal disruption, and reduced vitality are often presented as possible side effects of treatment, but men need to understand something clearly: these outcomes are not rare surprises. In many cases, they are predictable consequences of aggressive prostate cancer treatment. They represent real tradeoffs that can significantly alter quality of life for years, and sometimes permanently.

This is where the conversation becomes uncomfortable, because it forces medicine to confront a difficult question. If the risks and harms of treatment are well established, yet the survival benefit remains uncertain for many men with early-stage disease, then we have an obligation to slow down and think more critically about the decisions being made.

Are we meaningfully improving long-term outcomes, or are we exposing men to guaranteed harm in pursuit of benefits that may never materialize?

The Problem With Biopsy-Driven Decisions

A Risk-Based Model Without Tissue Damage

I believe there is a better way to approach prostate cancer, one rooted in risk assessment and thoughtful decision-making rather than reflexive intervention. Too often, men are pushed into binary choices: biopsy or no biopsy, treatment or no treatment, surgery or radiation. That framework oversimplifies a far more complex disease and often creates pressure to act before the full picture is understood.

My approach focuses on understanding biological behavior through careful monitoring and imaging rather than immediately pursuing invasive procedures. PSA trends matter. Prostate Health Index matters. MRI findings matter. PI-RADS scoring matters. Each of these tools provides useful information, and when interpreted together, they help create a much clearer picture of risk.

The goal is not to ignore risk or avoid difficult decisions. The goal is to understand risk more intelligently.

If PSA trends remain stable, PHI remains controlled, and MRI findings show no evidence of aggressive progression, then the conversation changes. The focus shifts away from destruction and toward containment. Cancer confined within the prostate behaves very differently from cancer that has spread beyond the gland.

This is where nuance matters. Not every rise in PSA is dangerous, not every abnormal finding requires immediate action, and not every prostate cancer behaves in a way that justifies aggressive intervention. The mistake is reacting emotionally to isolated data without understanding what it truly means. The better approach is to slow down, evaluate the trend, study the biology, and make decisions rooted in real risk, thoughtful analysis, and long-term strategy rather than fear.

Repurposed Drug Therapy and Biological Control

At the core of my approach is repurposed drug therapy, using medications with long-established safety profiles to influence cancer biology, metabolism, and immune function without destroying vitality in the process. This is a very different philosophy from conventional oncology, which often focuses almost entirely on aggressively attacking cancer cells, even when that approach comes at significant cost to the patient’s overall health and quality of life.

I believe the better strategy is to ask a different question. Instead of focusing only on how to destroy cancer, we should also ask how to create a biological environment in which cancer is less likely to grow, spread, or thrive.

Medications such as metformin, sirolimus, doxycycline, low-dose naltrexone, and statins continue to appear throughout cancer research because they influence pathways closely tied to cancer growth, inflammation, metabolism, and immune regulation. These medications are not miracle cures, and I do not present them that way. They do not offer certainty, and they are not intended to replace thoughtful medical decision-making.

The real goal is not simply to target cancer in isolation, but to improve the biological terrain in which that cancer exists. By shifting the internal environment to make it less favorable for cancer progression, we often improve much more than prostate health alone. Better metabolic function, lower inflammation, reduced cardiovascular risk, greater resilience, and preservation of strength, energy, and vitality all become part of the equation.

This is where I believe the conversation around cancer treatment needs to evolve. The goal should not simply be attacking cancer at all costs. The goal should be improving the health of the man living with the disease while reducing the biological conditions that allow cancer to progress.

Why Hormone Suppression Deserves More Scrutiny

Few treatments illustrate the tradeoff between cancer control and quality of life more clearly than androgen deprivation therapy, also known as hormone suppression. This is one of the most aggressive interventions used in prostate cancer care, yet I believe far too little attention is given to its long-term impact on the man receiving it.

I am often surprised by how casually this treatment is recommended.

Hormone suppression guarantees physiological consequences. Fatigue, muscle loss, weight gain, depression, cognitive decline, metabolic dysfunction, and increased cardiovascular risk are not rare complications. They are common and predictable outcomes of suppressing testosterone, one of the most important hormones for maintaining strength, resilience, energy, and vitality in men.

Too often, success is defined by what happens to the PSA. The number goes down, and that is viewed as a win. But this is where modern medicine often confuses markers with outcomes. Lowering a lab value is not the same as improving health. Suppressing testosterone may reduce PSA and temporarily slow disease progression, but it can also profoundly affect how a man feels, functions, and lives.

Before starting hormone suppression, men should clearly understand what they may gain, what they may lose, and whether the expected benefit truly justifies the cost. In some advanced cases, androgen deprivation therapy may have a meaningful role. But it should never be presented as a benign or consequence-free intervention.

Because the real question is not simply whether the treatment lowers PSA. The real question is what that treatment does to the man.

The Goal Is Not Treatment. The Goal Is Avoiding Regret.

This is ultimately what Fight Cancer Like a Man is about. It is not about promising guarantees, because there are none in medicine. It is not about rejecting every conventional treatment or insisting that surgery, radiation, or other oncology tools never have a role. There are situations where conventional treatment may be appropriate and even necessary. The real issue is not whether treatment exists. The real issue is whether men are being given the clarity, time, and information needed to make thoughtful decisions about when treatment truly makes sense.

At its core, this is about informed decision-making. It is about understanding tradeoffs. It is about recognizing that every decision carries consequences, both immediate and long-term. Too many men make life-changing decisions under pressure, driven by fear, urgency, and incomplete information. That is where regret is born.

The strongest decisions are rarely made in panic. They are made through clear thinking, thoughtful analysis, and honest conversations about long-term consequences. They are made by stepping back and asking harder questions about risk, benefit, quality of life, and what truly matters in the years ahead.

Because the goal should never be treatment for the sake of treatment. The goal should be making thoughtful decisions that preserve both longevity and quality of life. Prostate cancer care should not be reduced to simply eliminating a tumor or lowering a lab value. It should be about protecting the things that matter most over the long term.

Strength matters. Vitality matters. Independence matters. Dignity matters. They are central to how a man lives, functions, and experiences life after a diagnosis. Every treatment decision should be weighed against what it may cost, not just what it promises. That is the standard every man should demand when facing prostate cancer.

If you have been diagnosed, if your PSA is rising, or if you are being pressured into making rapid decisions, slow down and make sure you fully understand your options before moving forward. The decisions you make today may affect your health, function, and quality of life for years to come.

Choose carefully.

If you want a more thoughtful and strategic approach to prostate cancer care, start by reading Fight Cancer Like a Man, join our membership community, or schedule a consultation to better understand your options before making irreversible decisions.

That is what it means to fight cancer like a man.

About Dr. Stephen Petteruti

Dr. Stephen Petteruti is a physician focused on men’s health, hormone optimization, longevity, and prostate cancer care. His approach challenges conventional thinking by focusing on root causes, metabolic health, and long-term vitality. His goal is not simply helping patients live longer, but helping them preserve strength, energy, resilience, and quality of life as they age.

Learn more at Dr. Stephen Petteruti

References

1. Al Hussein Al Awamlh B, Wallis CJD, Penson DF, et al. Functional Outcomes After Localized Prostate Cancer Treatment. JAMA. 2024;331(4):302–317. doi:10.1001/jama.2023.26491
2. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2023;388(17):1547-1558. doi:10.1056/NEJMoa2214122
3. Ishwariya Rajendran, Kang-Lung Lee, Liness Thavaraja, Tristan Barrett, Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making, British Journal of Radiology, Volume 97, Issue 1153, January 2024, Pages 113–119, https://doi.org/10.1093/bjr/tqad027
4. Kang SK, Mali RD, Prabhu V, Ferket BS, Loeb S. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness. Radiology. 2021;300(3):594-604. doi:10.1148/radiol.2021204321
5. Osses DF, Arsov C, Schimmöller L, et al. Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. J Pers Med. 2020;10(4):270. Published 2020 Dec 10. doi:10.3390/jpm10040270
6. Schoots IG, Osses DF, Drost FH, et al. Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. Transl Androl Urol. 2018;7(1):132-144. doi:10.21037/tau.2017.12.29
7. Viana PCC, Queiroz MA, Ferreira FO, et al. Multiparametric MRI combined with PSA density as a noninvasive rule-out strategy in active surveillance for prostate cancer. BJUI Compass. 2025;6(9):e70079. Published 2025 Sep 22. doi:10.1002/bco2.70079